Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
Saved in:
| Title: | Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. |
|---|---|
| Authors: | Hong, David S.1, Garrido‐Laguna, Ignacio1, Ekmekcioglu, Suhendan2, Falchook, Gerald S.1, Naing, Aung1, Wheler, Jennifer J.1, Fu, Siqing1, Moulder, Stacy L.1, Piha‐Paul, Sarina1, Tsimberidou, Apostolia M.1, Wen, YueJin1, Culotta, Kirk S.3, Anderes, Kenna4, Davis, Darren W.4, Liu, Wen4, George, Goldy C.1, Camacho, Luis H.1, Percy Ivy, Susan5, Kurzrock, Razelle1,6 |
| Source: | Cancer (0008543X). Jul2014, Vol. 120 Issue 14, p2164-2173. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 0008543X |
|---|---|
| DOI: | 10.1002/cncr.28701 |
